560 related articles for article (PubMed ID: 23775260)
1. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Bonderman D; Ghio S; Felix SB; Ghofrani HA; Michelakis E; Mitrovic V; Oudiz RJ; Boateng F; Scalise AV; Roessig L; Semigran MJ;
Circulation; 2013 Jul; 128(5):502-11. PubMed ID: 23775260
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
[TBL] [Abstract][Full Text] [Related]
3. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
[TBL] [Abstract][Full Text] [Related]
4. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
5. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
Bonderman D; Pretsch I; Steringer-Mascherbauer R; Jansa P; Rosenkranz S; Tufaro C; Bojic A; Lam CSP; Frey R; Ochan Kilama M; Unger S; Roessig L; Lang IM
Chest; 2014 Nov; 146(5):1274-1285. PubMed ID: 24991733
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.
Mascherbauer J; Grünig E; Halank M; Hohenforst-Schmidt W; Kammerlander AA; Pretsch I; Steringer-Mascherbauer R; Ulrich S; Lang IM; Wargenau M; Frey R; Bonderman D
Wien Klin Wochenschr; 2016 Dec; 128(23-24):882-889. PubMed ID: 27590259
[TBL] [Abstract][Full Text] [Related]
7. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
8. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
D'Armini AM; Ghofrani HA; Kim NH; Mayer E; Morsolini M; Pulido-Zamudio T; Simonneau G; Wilkins MR; Curram J; Davie N; Hoeper MM
J Heart Lung Transplant; 2015 Mar; 34(3):348-55. PubMed ID: 25813765
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.
Galiè N; Grimminger F; Grünig E; Hoeper MM; Humbert M; Jing ZC; Keogh AM; Langleben D; Rubin LJ; Fritsch A; Davie N; Ghofrani HA
J Heart Lung Transplant; 2017 May; 36(5):509-519. PubMed ID: 28190787
[TBL] [Abstract][Full Text] [Related]
10. Riociguat for pulmonary hypertension.
Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
[TBL] [Abstract][Full Text] [Related]
11. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA
J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961
[TBL] [Abstract][Full Text] [Related]
12. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
Wagner F; Yeter R; Bisson S; Siniawski H; Hetzer R
Crit Care Med; 2003 May; 31(5):1421-8. PubMed ID: 12771613
[TBL] [Abstract][Full Text] [Related]
13. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
[TBL] [Abstract][Full Text] [Related]
14. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
15. [Riociguat - a stimulator of soluble guanylate cyclase: a new mode of action helps patients with pulmonary hypertension].
Kreutzkamp B
Med Monatsschr Pharm; 2013 Dec; 36(12):442-7. PubMed ID: 24450268
[No Abstract] [Full Text] [Related]
16. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.
Barst RJ; Ivy DD; Gaitan G; Szatmari A; Rudzinski A; Garcia AE; Sastry BK; Pulido T; Layton GR; Serdarevic-Pehar M; Wessel DL
Circulation; 2012 Jan; 125(2):324-34. PubMed ID: 22128226
[TBL] [Abstract][Full Text] [Related]
18. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
19. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
[TBL] [Abstract][Full Text] [Related]
20. Riociguat for pulmonary hypertension.
Cannon JE; Pepke-Zaba J
Expert Rev Clin Pharmacol; 2014 May; 7(3):259-70. PubMed ID: 24580082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
